Enbrel Indications/Uses

Rheumatoid Arthritis: Etanercept is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Etanercept can be initiated in combination with methotrexate (MTX) or used alone.
Psoriatic Arthritis: Etanercept is indicated for reducing signs and symptoms of active psoriatic arthritis in patients with psoriatic arthritis. Etanercept can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
Axial Spondyloarthritis: Ankylosing spondylitis (AS): Etanercept is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Non-radiographic axial spondyloarthritis: Etanercept is indicated for the treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence, who have had an inadequate response to, or are intolerant to, conventional therapy.
Plaque Psoriasis: Etanercept is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Juvenile Idiopathic Arthritis: Treatment of polyarticular-course juvenile idiopathic arthritis (JIA) in children and adolescents from the age of 2 years when the response to one or more DMARDs has proved inadequate.
Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.
Pediatric Plaque Psoriasis: Etanercept is indicated for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.